In light of the British Medical Journal's controversial article asserting that pharma KOLs are no more than glorified sales reps, do you think there should be more transparency in industry's dealings with influential doctors?
A settlement between Pfizer and Ranbaxy means that the latter will be able to start selling its generic form of the cholesterol drug Lipitor by late 2011.